Kabotyanski, Katherine E. http://orcid.org/0000-0001-9003-1588
Najera, Ricardo A.
Banks, Garrett P. http://orcid.org/0000-0001-6292-977X
Sharma, Himanshu
Provenza, Nicole R. http://orcid.org/0000-0002-6952-5417
Hayden, Benjamin Y.
Mathew, Sanjay J. http://orcid.org/0000-0002-2715-6641
Sheth, Sameer A. http://orcid.org/0000-0001-8770-8965
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32GM136611)
BRASS: Baylor Research Advocates for Student Scientists
Article History
Received: 13 November 2023
Revised: 14 May 2024
Accepted: 20 May 2024
First Online: 7 June 2024
Competing interests
: Dr. Sheth is a consultant for Boston Scientific, Neuropace, Zimmer Biomet, Koh Young, Sensoria Therapeutics, and Varian Medican and is co-founder of Motif Neurotech. Dr. Mathew has served as a consultant for Abbott, Almatica Pharma, Biohaven, BioXcel Therapeutics, Boehringer-Ingelheim, Brii Biosciences, Clexio Biosciences, COMPASS Pathways, Delix Therapeutics, Douglas Pharmaceuticals, Eleusis, Engrail Therapeutics, Freedom Biosciences, Janssen, Liva Nova, Levo Therapeutics, Merck, Neumora, Neurocrine, Perception Neurosciences, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, Sunovion, Xenon Pharmaceuticals, and XW Pharma.